Page last updated: 2024-08-24

halofuginone and Carcinoma, Ductal, Pancreatic

halofuginone has been researched along with Carcinoma, Ductal, Pancreatic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Carlson, M; Elahi-Gedwillo, KY; Provenzano, PP; Zettervall, J	1

Other Studies

1 other study(ies) available for halofuginone and Carcinoma, Ductal, Pancreatic

Article	Year
Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma. Cancer research, 2019, 01-15, Volume: 79, Issue:2 Topics: Animals; Biophysical Phenomena; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Humans; Macrophages; Mice; Pancreatic Neoplasms; Piperidines; Quinazolinones; Random Allocation; Stromal Cells; Tumor Microenvironment	2019

Article

Year

Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma.

Cancer research, 2019, 01-15, Volume: 79, Issue:2

Topics: Animals; Biophysical Phenomena; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Humans; Macrophages; Mice; Pancreatic Neoplasms; Piperidines; Quinazolinones; Random Allocation; Stromal Cells; Tumor Microenvironment

2019